By mimicking the action of the glucagon-like peptide-1 (GLP-1) hormone, these medications slow gastric emptying, increase the feeling of fullness, and reduce calorie intake, resulting in significant weight loss over time
The second-line ADMs included GLP1-R agonists, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sodium-glucose cotransporter 2 (SGLT2) inhibitors
[1] [2] GLP-1 receptor agonists bind to GLP-1 receptors located throughout the body, including the pancreas, gastrointestinal tract, and central nervous system
Embarazo y lactancia : datos insuficientes, uso desaconsejado por precaucin
It has the most published data on CRP reduction and inflammatory marker improvement
Their findings also showed a lower risk of neurocognitive disorders such as Alzheimers and dementia